Table 4.
Toxicities of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer treated in later-line setting. The third and fifth columns present data regarding the total number of patients and number of series for all grades and grade 3/4 toxicities, respectively.
| Toxicity | % All Grades | Total Patients with Data/Series with Data | % Grades 3 and 4 | Total Patients with Data/Series with Data |
|---|---|---|---|---|
| Neutropenia | 68% | 281/6 | 44.9% | 441/8 |
| Anemia | 43% | 302/7 | 12.6% | 420/7 |
| Thrombocytopenia | 28% | 271/6 | 3.9% | 389/6 |
| Asthenia/fatigue | 50.5% | 208/6 | 3.7% | 326/6 |
| Anorexia | 29.3% | 215/4 | 0.3% | 354/5 |
| Diarrhea | 28.4% | 271/6 | 1.8% | 389/6 |
| Hypertension | 15.6% | 270/6 | 1.5% | 388/6 |
| Nausea/GI toxicity | 53.9% | 271/6 | 2.3% | 389/6 |
| Proteinuria | 33.3% | 267/6 | 3.9% | 385/6 |
| Hemorrhage | 12.1% | 124/3 | 0.8% | 124/3 |